Feb 6, 2025 · Alumis and ACELYRIN and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Alumis’ directors and executive officers is set forth in Alumis’ registration statement on Form S-1/A (File No. 333-280068), which was filed with ...

1 day ago · Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 million on February 6. Upon completion of the deal, which is expected to ...

Feb 6, 2025 · Alumis and ACELYRIN had cash, cash equivalents and marketable securities of approximately $289 million and approximately $448 million, respectively, on a preliminary basis, as of December 31, 2024

Feb 7, 2025 · Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical biopharma company. The merged company will focus on ...

Alumis and ACELYRIN and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Alumis’s directors and executive officers is set forth in Alumis’s registration statement on Form S-1/A (File No. 333-280068), which was ...

Feb 6, 2025 · Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. Alumis and Acelyrin had cash, cash...

Feb 7, 2025 · Prior to the merger, Acelyrin and Alumis were struggling with depressed share prices. The two biotechs went public in 2023 and 2024, respectively, in large initial public offerings — Acelyrin netted $540 million, while Alumis raised $250 million — but both have since lost most of their market value. Acelryin has already changed up its strategy.

Feb 7, 2025 · With Acelyrin sitting on $448 million in cash and equivalents and Alumis bringing $289 million to the table, Alumis expects that postmerger it will have a cash runway into 2027.

Feb 7, 2025 · Both Alumis and Acelyrin are new to the Nasdaq. Alumis made its bid in June 2024, eventually making a modest $250 million, slightly lower than its initial target. Acelyrin, meanwhile, was ahead by more than a year, with an initial public offering (IPO) in April 2023 that bagged the biotech $540 million —one of the largest that year.

Feb 6, 2025 · Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own ...